Alison Luckey

2 September 2021

Alison joined GARDP in September 2021 as Medical Lead for the Zoliflodacin program.
As a Pharmaceutical Physician, she brings a wealth and breadth of experience to the team as a result of her 22-year clinical research career, the last 8 years of which have been within late phase drug development in the anti-infectives therapeutic area.  As EFPIA Lead (Astra Zeneca and Pfizer) for Innovative Medicine’s Initiative’s (IMI) COMBACTE CARE consortium, she has most recently been instrumental in developing and maintaining essential public-private collaborations, leveraging unique opportunities and novel ways of working, to successfully deliver the first interventional Phase 2a study of the program and start-up of a Phase 3 program through two corporate transitions and a pandemic.

Prior to this, Alison has worked as a Clinical Research Physician and Principal Investigator in early phase development in both the United Kingdom and New Zealand.  Together with colleagues, she established a CRO in New Zealand with a 10-bedded facility specialising in early phase development, including First in Man studies and providing an end-to-end service for small biotech companies as well as large pharma.   During this time, she was Deputy Chair of the Upper South Regional Ethics Committee, Ministry of Health, New Zealand.

Alison is a medical graduate (Southampton, UK, 1992) with post graduate clinical experience in Obstetrics & Gynaecology; she holds the Diploma of Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians.